FORBEST ® - Flunisolide
FORBEST ® is a Flunisolide-based drug
THERAPEUTIC GROUP: Medicines for obstructive disorders of the respiratory tract
Indications FORBEST ® - Flunisolide
FORBEST ® is indicated in the treatment of allergic diseases of the respiratory tract such as bronchial asthma, chronic asthmatic bronchitis and chronic or seasonal allergic rhinitis.
Mechanism of action FORBEST ® - Flunisolide
Flunisolide, the active ingredient of the FORBEST ® medicinal product, is a highly active corticosteroid for topical administration, successfully used in the treatment and prevention of allergic obstructive symptoms of the respiratory tract.
Taken in the form of a nasal spray or nebulization solution, it carries out its therapeutic action locally in a few minutes, causing, like other corticosteroids, a significant reduction in the inflammatory degree of the respiratory mucosa by inhibiting the synthesis of inflammatory cytokines and mediators of inflammation.
All this takes the form of the reduced degree of inflammatory activation of the mucosa, in the inhibition of the recruitment mechanisms of the inflammatory cells and circulating basophils, in the decongestant action on the mucosa of the upper respiratory tract, in the control of mucus secretion and therefore in a clear improvement of the complained symptoms.
The amount of drug absorbed through these inflamed mucous membranes is metabolized in the liver and immediately catabolized into a pharmacologically inactive metabolite.
Studies carried out and clinical efficacy
TOPICAL THERAPY VS SYSTEMIC THERAPY
Pediatr Pulmonol. 2013 Aug 8. doi: 10.1002 / ppul.22846. [Epub ahead of print]
Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review.
Beckhaus AA, Riutort MC, Castro-Rodriguez JA.
Work that demonstrates the absence of differences between inhaled or systemic administration of corticosteroids for the treatment of asthma exacerbation, in terms of therapeutic efficacy.
It is therefore evident, however, that topical administration could spare some of the side effects classically linked to systemic therapy.
FLUNISOLIDE AND GROWTH
Ann Allergy Asthma Immunol. 2011 Oct; 107: 323-9. doi: 10.1016 / j.anai.2011.07.017. Epub 2011 Sep 3.
Linear growth and bone maturation are unaffected by 1 year of therapy with inhaledflunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial.
Bensch GW, Greos LS, Gawchik S, Kpamegan E, Newman KB.
Double-blind clinical study demonstrating that local administration of Flunisolide, even if continued for prolonged periods, does not suppress the growth or correct maturation of the bone in very young patients.
FLUNISOLIDE AND NON ALLERGIC RHINITE
Int J Immunopathol Pharmacol. 2011 Apr-Jun; 24: 401-9.
Intranasal flunisolide treatment in patients with non-allergic rhinitis.
Varricchio A, Capasso M, De Lucia A, Avvisati F, Varricchio AM, Bettoncelli G, Ciprandi G.
Work that seeks to extend the potential clinical applications of Flunisolide by demonstrating its clinical efficacy even in cases of non-allergic rhinitis characterized by inflammation and hyperactivity of the nasal mucosa.
Method of use and dosage
Nebulized solution of 0.5 - 1 - 2 mg of Flunisolide per ml of solution.
The definition of the dosage and the therapeutic scheme to follow during treatment is up to the doctor after having carefully assessed the patient's state of health and the severity of his clinical picture.
In general, it is recommended to inhale 1 mg of Fluticasone twice a day in adults.
FORBEST ® warnings - Flunisolide
The administration of FORBEST ® should necessarily be preceded by a careful medical examination aimed at clarifying the etiological origin of the clinical picture complained of and therefore any prescriptive appropriateness.
Corticosteroid therapy, even if inhaled, poses some important precautions to consider, such as:
- avoid prolonged administration over time, potentially responsible for hypersensitivity reactions and various symptoms;
- consider the greater susceptibility of the individual to pathologies of infectious origin;
- periodically check adrenal function;
- avoid exceeding recommended doses and times;
- combine therapy with vasoconstrictors in the event that there is a massive congestion of the mucous membranes, such as to make breathing difficult.
It is also worth mentioning the inadequacy of Flunisolide in the treatment of the acute phase of asthma.
The use of Corticosteroids, without clinical need, is prohibited in and out of competition.
It is recommended to store the drug out of the reach of children.
PREGNANCY AND BREASTFEEDING
The absence of studies able to fully characterize the safety profile of Flunisolide for the health of the fetus and infant, extends the aforementioned contraindications to the use of FORBEST ® also to pregnancy and the subsequent breastfeeding period.
No drug interactions worthy of clinical note are currently known, although the concomitant intake of inhibitors or inducers of the cytochromial system would be able to alter the pharmacokinetic characteristics of any absorbed portion of Flunisolide.
Contraindications FORBEST ® - Flunisolide
The use of FORBEST ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with active or quiescent viral and tuberculous infections and in pregnant and lactating women.
Undesirable Effects - Side Effects
Therapy with inhaled corticosteroids such as Flunisolide, especially in particularly sensitive patients, could lead to the onset of local adverse reactions such as nasal irritation, epistaxis, rhinorrhea, sore throat, hoarseness and irritation of the oral cavity.
Fortunately, systemic adverse reactions typical of corticosteroids worthy of clinical note are rarer.
FORBEST ® is a prescription drug.
The information on FORBEST ® - Flunisolide published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.